ArticleClinical and molecular allergy : CMA2015
Bilastine: new insight into antihistamine treatment.
Article in Clinical and molecular allergy : CMA, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 81 citations in OpenAlex.
- Lack of Clinical Relevance of Bilastine-Food Interaction in Healthy Volunteers: A Wheal and Flare Study.International archives of allergy and immunology · 2022Trial
- Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.European journal of pediatrics · 2020Trial
- Montelukast and Bilastine Combination Therapy in Allergic Rhinitis: A Narrative Review of Evidence.Cureus · 2026Review
- Pregnancy Outcome Following First-Trimester Exposure to Bilastine: A Comparative Observational Cohort Study from the Israeli Teratology Information Service.Journal of clinical medicine · 2026Article
- The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study.Scientific reports · 2025Article
- An Outline on Benzimidazole Containing Marketed Drugs with Proton Pump Inhibitor and HMini reviews in medicinal chemistry · 2025Review
- Bilastine Reimagined: A Comprehensive Exploration of Pruritus Management With a Novel Antihistamine.Cureus · 2024Review
- Treatment of Allergies to Fur Animals.International journal of molecular sciences · 2024Review
- The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro study.Scientific reports · 2024Article
- Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24 h Postadministration.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2022Article
- Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis.Frontiers in pharmacology · 2021Review
- A case of bleomycin-induced flagellate dermatitis: A case report.SAGE open medical case reports · 2021Article
- Elucidation of Inverse Agonist Activity of Bilastine.Pharmaceutics · 2020Article
- Article
- Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.Drugs & aging · 2019Article
- Economic Burden of the Inadequate Management of Allergic Rhinitis and Urticaria in Asian Countries Based on the GA²LEN Model.Allergy, asthma & immunology research · 2018Article
- International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.International forum of allergy & rhinology · 2018Article
- Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia.Clinical and molecular allergy : CMA · 2017Article
- Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.Therapeutics and clinical risk management · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bilastine is a new second generation H1-antihistamine recently approved for the symptomatic treatment of allergic rhinitis (AR) and chronic urticaria (CU). Bilastine epitomizes the evolution of research on antihistamines concerning both efficacy and safety. In AR treatment, a number of large controlled clinical trials documented its efficacy, as assessed by improvement of all nasal and ocular symptoms and quality of life. These outcomes show that bilastine meets current EAACI/ARIA criteria for medications used in the treatment of AR. Also in CU, the review of the literature indicates that once-daily treatment with bilastine 20 mg was effective in managing symptoms and improving patient's quality of life. Concerning safety and tolerability, the profile of bilastine is very similar to placebo and in particular the adverse effects on central nervous system are insignificant. The balance of efficacy and safety of bilastine is particularly helpful when dosages higher than standard are needed to control the symptoms, as frequently occurs in patients with urticaria, in whom antihistamines doses up to four times the standard dose may be administered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.